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Base editors are RNA-guided deaminases that enable site-specific nucleotide transitions. The 
targeting scope of these Cas-deaminase fusion proteins critically depends on the availability of a 
protospacer adjacent motif (PAM) at the target locus and is limited to a window within the 
CRISPR-Cas R-loop, where single stranded (ss)DNA is accessible to the deaminase. Here, we 
reason that the Cas9-HNH nuclease domain sterically constrains ssDNA accessibility, and 
demonstrate that omission of this domain expands the editing window. By exchanging the HNH 
nuclease domain with an adenosine deaminase we furthermore engineer adenine base editor 
variants (HNHx-ABE) with PAM-proximally shifted editing windows. This work expands the 
targeting scope of base editors, and provides base editor variants that are substantially smaller. 
It moreover informs of potential future directions in Cas9 protein engineering, where the HNH 
domain could be replaced by other enzymes that act on ssDNA.  
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INTRODUCTION: 
CRISPR-Cas systems provide adaptive immunity to bacteria to defend them against foreign genetic 
elements. A small number of these systems have successfully been adopted for genome editing in 
mammalian cells, transforming biomedical research and therapeutics (1–3). A paradigmatic example is 
the SpCas9 nuclease from Streptococcus pyogenes. Recruitment of SpCas9 to a desired genomic locus 
via a single guide (sg)RNA allows facile and efficient genome editing by generating site-specific double 
stranded (ds)DNA breaks. Precise genome editing via such dsDNA breaks, however, relies on template 
DNA for homology directed repair (HDR) that is inefficient in most mammalian cell types and leads to 
repair via alternative, error-prone end-joining pathways that generate frameshift mutations and gene 
knockouts.  
Recent modifications to the highly modular SpCas9 protein resulted in sophisticated genome editing 
technologies, such as base editors (BEs), which enable genome editing without dsDNA break formation. 
BEs allow precise conversion of A-to-G and C-to-T nucleobases or vice versa via nucleotide 
deamination independent of dsDNA breaks and HDR (4, 5), and thus have great potential for research- 
and therapeutic applications (6–8). They are mono- or heterodimers of ssDNA-specific deaminases 
fused N-terminally to catalytically impaired CRISPR class II effectors such as Cas9 or Cas12a (4, 5, 9). 
Upon binding to a protospacer element, Cas9 complexed with the sgRNA forms an R-loop, making the 
non-target DNA strand (the target DNA strand is bound to the sgRNA) accessible to ssDNA-specific 
deaminases. Notably, Cas9 and Cas12 proteins require PAM sites for DNA binding, restricting the 
targeting scope of base editors to nucleobases that lie within a defined proximity to these motifs. 
To address the limited PAM compatibility, various base editors were generated by fusing deaminases 
to Cas variants with less restrictive PAM requirements (10–14). While these efforts considerably 
expanded the targeting scope of BEs, currently, no PAMless Cas9 and Cas12 variants have been 
developed, and several T>C and G>A disease-causing SNPs remain untargetable. Pursuing a different 
approach, recent work has led to base editor variants with slightly extended editing windows: Huang et 
al. fused deaminases to circularly permuted Cas9 proteins (15), and Wang et al. incorporated the 
cytidine deaminase rAPOBEC1 into the PAM-interacting (PI) domain of SpCas9 (16). Similarly, 
incorporation of laboratory evolved TadA7.10 (4) into the PI domain led to a PAM-proximal extension 
of the editing window of adenine base editors (ABEs) (ABEmax PI - Fig 1a and b). 
Here, we report a novel ABE variant, where the HNH nuclease domain of SpCas9 is replaced by TadA. 
Compared to classical ABEs this variant has a PAM-proximally shifted editing window, and is 
significantly reduced in size. 
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RESULTS AND DISCUSSION: 
Structural data suggest that the HNH nuclease domain (amino acids 775-908) in SpCas9 likely prevents 
the deaminase from accessing the ssDNA substrate at positions 13-15 counting from the PAM-distal 
end of the protospacer (Fig. 1c). Importantly, the HNH domain is not required for Cas9 to bind its target 
DNA and form an R-loop (17), and nickase activity is not essential for base editing (Fig 1e) (17). We 
therefore reasoned that omission of the HNH domain might improve accessibility and editing at PAM-
proximal positions. To test our hypothesis, we engineered ABEmax7.10 ∆HNH. Compared to the 
original ABE7.10 construct, where a heterodimer of wild-type (WT) and evolved TadA-7.10 is C-
terminally linked to a “nickase” or “dead” version of SpCas9, in the ABEmax7.10 ∆HNH construct the 
TadA heterodimer is C-terminally fused to a SpCas9 variant that lacks the HNH domain (Fig.1d). 
Although the highest editing rates remained at positions that are also efficiently targeted with 
ABEmax7.10, ABEmax7.10 ∆HNH allowed editing at positions 12 and 14 (Fig. 1e). Our data therefore 
suggest that the HNH domain of SpCas9 indeed constrains access of TadA to PAM-proximal ssDNA 
nucleobases.  
Simply expanding the editing window of BEs has the disadvantage that it can generate additional 
undesired non-target nucleotide (bystander) edits within the ssDNA of the R-loop. This led us to 
investigate whether directly replacing the HNH domain with the adenine deaminase (HNHx-ABE) leads 
to a shift rather than a broadening of the editing window (Fig. 2a, b). Before incorporating a deaminase 
domain in place of the HNH domain in SpCas9, we first exchanged the HNH domain for a superfolder 
(sf)GFP. Transfection of these constructs into HEK293T cells demonstrated localization of GFP to the 
nucleus (Fig. 2c), indicating that the HNH domain can be exchanged with another protein domain 
without substantial misfolding and degradation of Cas9. In a next step, we engineered HNHx-
ABEmax7.10 by incorporating the evolved deaminase domain from ABEmax7.10 (4) with 20 different 
peptide linker combinations into SpCas9 lacking the HNH domain. Using high throughput sequencing 
(HTS), editing efficiencies of constructs with different linker combinations were compared two days 
after transfection (Fig. 2d). In the most promising construct, a GGS-linker was used to join SpCas9 
S793 to the TadA7.10 N-terminus, and a SGG-linker was used to join the TadA7.10 C-terminus to 
SpCas9 R919. This construct (HNHx-ABEmax7.10) exhibited a distinct shift in the editing window 
PAM-proximally, with up to 13.7% editing five days after transfection (Fig. 3a). Notably, when we 
exchanged the HNH domain with the cytosine deaminases FERNY, a laboratory evolved APOBEC 
variant (19), we observed a similar shift in the editing window, albeit with very low editing rates (Suppl. 
Fig. 1). While these could be increased by exchanging FERNY with the cytidine deaminase PmCDA1, 
HNHx-PmCDA1 constructs induced broad deamination across the entire protospacer region, leading to 
significant bystander edits (Suppl. Fig. 1).  
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Phage assisted non-continuous and continuous evolution has enabled the development of TadA variants 
with increased deaminase activity (20). To assess whether the use of these variants would improve 
editing rates of HNHx-ABEs, we next exchanged the TadA7.10 deaminase domain with hyperactive 
TadA8e, resulting in HNHx-ABE8e. As expected, we observed higher editing rates with HNHx-ABE8e 
compared to HNHx-ABEmax7.10 (up to 19.7% - Fig.3b). Higher editing efficiencies, however, came 
at the cost of lower specificity, and the editing window was significantly broadened (Fig 3b). Depending 
on the target locus, base editing with HNHx-ABE8e could therefore enhance the chances of generating 
deleterious bystander mutations.  
Several recent studies have shown that ABEs induce substantial sgRNA-independent off-target 
deamination on the transcriptome, raising concerns about potential risks for clinical application (21–
23). Considering that TadA is not terminally fused but instead integrated into Cas9, and thus potentially 
constrained by HNHx-ABE architecture (Fig. 1b and 2c), we reasoned that transcriptome-wide off-
target editing might be reduced. However, while RNA-sequencing showed a decrease in off-target 
adenine deamination in HNHx-ABE8e treated cells compared to ABE8e treated cells, HNHx-
ABEmax7.10 showed a slight increase in off-target adenine deamination compared to ABEmax7.10 
(Suppl. Fig. 2). Interestingly, Gaudelli et al. recently reported an elevation in RNA off-target 
deamination when a TadA7.10 was fused to Cas9 as a monomer instead of a heterodimer (24), 
suggesting that enhanced transcriptome deamination in HNHx-ABEmax7.10 could result from the 
inability of TadA7.10 to form a heterodimer with wild-type TadA. 
To provide an example for the potential benefit of HNHx-ABE constructs over ABEs with N-terminally 
fused TadA, we next targeted a disease-causing mutation in the Fanconi anaemia complementation 
group A (FANCA) gene (c.3188G>A - Fig. 3c). Here, the only available canonical NGG PAM site 
positions the disease-causing mutation outside of the editing window of classical ABEs. When we 
transfected cells containing the FANCA c.3188G>A mutation with HNHx-ABE8e, we obtained 
considerably higher on-target editing compared to ABE8e or ABEmax7.10 (Fig. 3c). Notably, similar 
on-target editing could be obtained when using ABE8e-SpRY14, where an evolved Cas9 binds a 
downstream NCC PAM site, positioning the disease-causing mutation within reach of classical ABEs 
(Fig. 3b). However, compared to HNHx-ABE8e, ABE8e-SpRY led to more bystander mutations that 
resulted in non-synonymous mutations in the target gene. For correcting the FANCA c.3188G>A 
mutation, HNHx-ABE8e therefore provides a valuable alternative to current ABE variants.  
In this work we demonstrate that replacing the HNH domain of SpCas9 with a deaminase domain shifts 
the editing window of BEs PAM-proximally (from positions 4-8 to 9-16 for TadA7.10). This expands 
the targeting scope of currently available base editors, and enables targeting of additional disease-
causing mutations. Replacement of the HNH domain with TadA furthermore reduces the size of ABEs 
from 5.4kb to below 4.4kb, allowing the construction of single adeno-associated virus (AAV)-vectors 
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with minimal promoters for in vivo delivery. It is important to note, however, that editing rates of 
HNHx-ABEs were lower compared to ABEs with N-terminally fused TadA. In part, this is due to the 
absence of an HNH domain, as ABEmax7.10 lacking the HNH domain (ABEmax7.10 ∆HNH) also 
exhibited a reduction in editing rates compared to classical ABEmax7.10. Interestingly, this difference 
in editing was not caused by the lack of target strand nicking (dABEmax7.10 lacking nickase activity 
performed comparably to ABEmax7.10), suggesting that the role of the HNH domain in base editing 
goes beyond nicking of the target strand, and that it potentially also contributes to the structural integrity 
of the BE complex. Another potential reason for lower editing rates of HNHx-ABE constructs could be 
steric hindrance by the surrounding Cas9 protein and prevention of TadA dimerization (Suppl. Fig 3), 
as recent studies have demonstrated that TadA typically forms a dimer in its functional state (4, 20, 25). 
In the future, directed protein evolution or rational protein engineering strategies may nevertheless 
further refine HNHx-ABE constructs and enable editing efficiencies similar to classical ABEs. In 
addition, our approach of replacing the HNH domain could be extended to other effector enzymes that 
act on ssDNA, further expanding the Cas9-based genome editing tool box.  
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FIGURE LEGEND 
Fig 1 Approaches to increase substrate accessibility for base editing at PAM-proximal bases. a) 
Schematic domain organization of ABEmax7.10 and ABEmax PI1-3. ABEmax PI1-3 comprise an 
engineered SpCas9 (D10A) construct, where the TadA deaminase is integrated within the PI domain. 
ABEmax PI1, PI2, and PI3 use different linker lengths flanking the TadA deaminase. b) Editing 
efficiencies of ABEmax PI constructs are quantified by high throughput sequencing at 3 different 
endogenous loci. Values represent mean of three independent biological replicates performed on 
separate days ± s.d. c) Structural data (PDB: 6VPC) of adenine base editors with (left) and without 
(right) an HNH domain (indicated in red). Laboratory evolved, monomeric TadA deaminases indicated 
in orange and blue dimerize, and target the ssDNA substrate (turquoise). d) Schematic domain 
organization of ABEmax7.10 ∆HNH, where the HNH domain is replaced by a glycine-serine linker 
(Gly-Gly-Ser-Gly-Gly-Ser). e) High throughput sequencing data compares editing efficiencies of 
ABEmax7.10, dABEmax7.10 and ABEmax7.10 ∆HNH in endogenous loci in HEK293T cells. 
ABEmax7.10 retains nickase activity, nicking the target strand. Elimination of the nickase activity in 
ABEmax7.10 by introducing a H840A mutation in the HNH domain leads to dABEmax7.10. Complete 
removal of the HNH domain (that also abolishes nickase activity) in ABEmax7.10 results in 
ABEmax7.10 ∆HNH. Values represent mean of three independent biological replicates performed on 
separate days ± s.d. 
Fig 2 HNH domain substitution with sfGFP and ssDNA-specific deaminase domains. a) Schematic 
domain organization of Cas9 variants, where the HNH domain is replaced by a sfGFP or a ssDNA-
specific deaminase domain. b) Structural data of hypothetical Cas9 (PDB: 5F9R) constructs, where the 
HNH domain is omitted, replaced by sfGFP (PDB: 2B3P) or a TadA deaminase (PDB: 6VPC). 
Nucleotides (14-17) indicated in red are outside of a typical editing window of ABEmax7.10 c) 
Fluorescence microscopy of HEK293T expressing Cas9, where the HNH domain is replaced with 
sfGFP, with (top panel) and without (bottom panel) nuclear localization signals. Blue: Hoechst, green: 
GFP, scale bar: 20 µm. d) Heat map depicting different flanking amino acids of Cas9 and linkers to 
incorporate the TadA deaminase in place of the HNH domain. The TadA deaminase reading frame is 
as listed in the Supplementary Information. Editing efficiencies were quantified by high throughput 
sequencing indicated as % A-to-G conversion 2 days after transfection. The x-axis defines base 
conversions at adenine base positions within the protospacer.  
Fig 3 Targeting of endogenous loci. a) Editing efficiencies of different adenine bases within the 
protospacer region comparing ABEmax7.10. and HNHx-ABEmax7.10 in endogenous loci in HEK293T 
cells. Numbering starts with PAM-distal nucleotides. Values represent mean of three independent 
biological replicates performed on separate days ± s.d. b) Editing efficiencies of different adenine bases 
within the protospacer region comparing ABE8e and HNHx-ABE8e in endogenous loci in HEK293T 
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cells. Numbering starts with PAM-distal nucleotides. Values represent mean of three independent 
biological replicates performed on separate days ± s.d. c) Editing of a disease-causing c.3188G>A 
mutation in the FANCA gene comparing different ABEmax7.10, ABE8e and HNHx-ABE8e constructs. 
Green indicates the target base, orange a synonymous mutation and red a non-synonymous mutation. 
Values represent mean of three independent biological replicates performed on separate days ± s.d. 
Suppl. Fig 1 Heat map depicting different flanking amino acids of Cas9 and linkers to incorporate the 
FERNY (top) and PmCDA1 (bottom) deaminases in place of the HNH domain. The FERNY and 
PmCDA1 deaminase reading frames are listed in the Supplementary Information. Linkers that join Cas9 
and deaminase at different amino acid positions within the deaminase are indicated in brackets. 
Suppl. Fig 2 RNA-seq analysis determines transcriptome-wide RNA off-targets after transfection of 
ABEmax7.10, ABE8e, HNHx-ABEmax7.10 and HNHx-ABE8e constructs.  
Suppl. Fig 3 Different viewing angles of a hypothetical HNHx-ABE variant with a dimerized TadA. 
Subunits are colored as follows: Cas9 ∆HNH, grey; TadA linked to Cas9, blue; TadA from another 
molecule dimerizes to Cas9-bound TadA for functional deamination, orange.  
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METHODS 
General methods and cloning. PCR was performed using Q5 High-Fidelity DNA Polymerase (New 
England Biolabs). All base editor constructs were assembled using NEBuilder HiFi DNA Assembly 
(New England Biolabs). Plasmids expressing sgRNAs were cloned using T4 DNA Ligase (New 
England Biolabs).  
Cell culture and high-throughput sequencing. HEK293T cells (ATCC CRL-3216) were cultured in 
Dulbecco’s modified Eagle’s medium GlutaMax (Thermo Fisher Scientific), supplemented with 10% 
(v/v) fetal bovine serum (FBS) and 1% penicillin-streptomycin (Thermo Fisher Scientific) at 37°C and 
5% CO2. Cells were maintained at confluency below 90% and seeded on 96-well cell culture plates 
(Greiner). 12-16h after seeding, at approximately 70% confluency, cells were transfected using 0.5µl 
Lipofectamine 2000 (Thermo Fisher Scientific) and 400ng base editor plasmid DNA and 100ng sgRNA 
plasmids. Cells were incubated for 5 days. Genomic DNA was isolated by adding 10µl lysis buffer 
(10mM Tris-HCl at pH8.0, 2% Triton X and 1mM EDTA and 25µg/ml Proteinase K) to 30µl cell 
suspension. The lysate was incubated at 60°C for 60min, followed by a 95°C incubation for 10min. The 
lysate was diluted with ddH2O to a final volume of 100µl. 2µl of the diluted lysate was used for 
subsequent PCR reactions of 10µl using NEBNext High-Fidelity 2x PCR Master Mix. The PCR product 
was purified using Agencourt AMPure XP beads (Beckman Coulter), and amplified with primers 
containing sequencing adapters. The products were gel purified and quantified using the Qubit 3.0 
fluorometer with the dsDNA HS assay kit (Thermo Fisher Scientific). Samples were sequenced on an 
Illumina MiSeq.  
HTS data analysis. Sequencing reads were demultiplexed using MiSeq Reporter (Illumina), and 
analysed using a Matlab script as previously described (5). Values are shown as n=3 independent 
biological replicates over different days, with mean ± s.d. 
Microscopy. HEK293T cells were transfected with 50ng GFP-expressing plasmids in a 96 well plate, 
counterstained with Hoechst 33342 and imaged using a Zeiss Apotome. Imaging conditions and 
intensity scales were matched for all images. Images were analysed using Fiji ImageJ software (v1.51n). 
Linker determination and testing. Structural data from SpCas9 (PDB: 5F9R) was used to estimate 
linker lengths flanking deaminases in PyMol version 2.3.4. Different constructs with combinations of 
N- and C-terminal linkers were tested, editing efficiencies and activity windows determined by high-
throughput sequencing.  
Molecular graphics and analyses were done with UCSF ChimeraX, developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with 
support from National Institutes of Health R01-GM129325 and the Office of Cyber Infrastructure and 
Computational Biology, National Institute of Allergy and Infectious Diseases. 
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RNA-seq experiments and data analysis. RNA library preparation was performed using the TruSeq 
Stranded Total RNA kit (Illumina) with a ribosomal RNA (rRNA) deletion step. RNA-seq libraries 
were sequenced on an Illumina Novaseq machine with a sequencing depth of 140-200 Mio reads per 
sample. 
Quality control, pre-processing and alignment of RNA-seq reads. Quality of Illumina PE RNA-seq 
reads was evaluated by FastQC v0.11.7 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
Possible contaminations (genomic DNA, rRNA, Mycoplasma, etc.) were screened for using 
FastqScreen v0.11.1 (https://www.bioinformatics.babraham.ac.uk/projects/fastq_screen/) against a 
customized database that consists of SILVA rRNA (https://www.arb-silva.de/), UniVec 
(https://www.ncbi.nlm.nih.gov/tools/vecscreen/univec/), refseq mRNA sequences and selected genome 
sequences (human, mouse, arabidopsis, bacteria, virus, phix, lambda, and mycoplasma) 
(https://www.ncbi.nlm.nih.gov/refseq/). Illumina PE reads were pre-processed using Trimmomatic 
version 0.36 to trim off sequencing adaptors and low quality ends (average quality lower than 20 within 
a 4 nt window). Flexbar version 3.0.3 was used to remove the first 6 bases of each read, which showed 
priming bias introduced during library preparation. PE RNA-seq reads were generated with different 
read length (2X51 and 2X151). After adapter and quality trimming, if the read length was longer than 
50 nt, only the first 50 nt were kept for downstream STAR mapping and variant calling. Quality 
controlled reads (average quality 20 and above, read length 20 and above) were aligned to the reference 
genomes (human reference genome: GRCh38.p10, Ensembl release 91) using STAR version 2.7.0e 
with 2-passes mode. PCR-duplicates were marked using Picard version 2.9.0. Read alignments were 
comprehensively evaluated in terms of different aspects of RNA-seq experiments, such as sequence 
quality, gDNA and rRNA contamination, GC/PCR/sequence bias, sequencing depth, strand specificity, 
coverage uniformity and read distribution over the genome annotation, using R scripts in ezRun 
(https://github.com/uzh/ezRun/) developed at the Functional Genomics Center Zurich. 
RNA sequence variant calling and filtering. Variant calling from RNA-seq reads was performed 
according to GATK Best Practices (https://gatkforums.broadinstitute.org/gatk/discussion/3891/calling-
variants-in-rnaseq). In detail, GATK (version 4.1.2.0) tool SplitNCigarReads was applied to post-
processed the read alignments. Afterwards variants were called using HaplotypeCaller (GATK version 
4.1.2.0) on PCR-deduplicated, post-processed aligned reads. Variant loci in base-editor overexpression 
experiments were filtered to exclude sites without high-confidence reference genotype calls in the 
control experiment. For a given SNV, the read coverage in the control experiment should be >90th 
percentile of the read coverage across all SNVs in the corresponding overexpression experiment. Only 
loci having at least 99% of reads containing the reference allele in the control experiment were kept. 
Only sites with more than 10 reads mapping in the overexpression experiment were kept. The cutoff for 
RNA A to I conversion frequency was set to 0.1. 
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